Bruker (NASDAQ:BRKR) Receives New Coverage from Analysts at Barclays

Barclays assumed coverage on shares of Bruker (NASDAQ:BRKR) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $75.00 price objective on the medical research company’s stock.

BRKR has been the topic of several other reports. TD Cowen cut their price objective on Bruker from $74.00 to $72.00 and set a hold rating on the stock in a research report on Wednesday, August 7th. Citigroup reduced their price target on Bruker from $95.00 to $80.00 and set a buy rating on the stock in a research report on Wednesday, July 10th. The Goldman Sachs Group lowered their price objective on shares of Bruker from $72.00 to $60.00 and set a sell rating for the company in a research report on Tuesday, July 9th. Wells Fargo & Company initiated coverage on shares of Bruker in a research note on Tuesday, August 27th. They set an overweight rating and a $78.00 price objective on the stock. Finally, Wolfe Research downgraded shares of Bruker from an outperform rating to a peer perform rating in a research note on Monday, September 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $80.82.

Bruker Stock Performance

NASDAQ BRKR opened at $63.11 on Tuesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. Bruker has a 1-year low of $53.79 and a 1-year high of $94.86. The firm has a market capitalization of $9.17 billion, a P/E ratio of 22.95, a P/E/G ratio of 2.52 and a beta of 1.18. The business’s 50-day simple moving average is $65.13 and its 200-day simple moving average is $69.49.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.52. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The firm had revenue of $800.70 million for the quarter, compared to analysts’ expectations of $799.44 million. During the same period in the previous year, the company posted $0.50 earnings per share. Bruker’s revenue was up 17.4% compared to the same quarter last year. Equities analysts predict that Bruker will post 2.61 EPS for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were paid a $0.05 dividend. The ex-dividend date was Friday, August 30th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.32%. Bruker’s dividend payout ratio (DPR) is presently 7.27%.

Hedge Funds Weigh In On Bruker

A number of hedge funds have recently bought and sold shares of BRKR. Lifestyle Asset Management Inc. lifted its holdings in Bruker by 1.3% during the 1st quarter. Lifestyle Asset Management Inc. now owns 12,534 shares of the medical research company’s stock worth $1,177,000 after buying an additional 158 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Bruker by 20.0% during the second quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock worth $63,000 after purchasing an additional 165 shares during the last quarter. Securian Asset Management Inc. boosted its holdings in Bruker by 2.3% in the second quarter. Securian Asset Management Inc. now owns 7,766 shares of the medical research company’s stock worth $496,000 after purchasing an additional 175 shares during the period. Park Place Capital Corp increased its stake in Bruker by 19.4% during the first quarter. Park Place Capital Corp now owns 1,139 shares of the medical research company’s stock valued at $107,000 after purchasing an additional 185 shares during the last quarter. Finally, Covestor Ltd raised its holdings in shares of Bruker by 139.1% during the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after purchasing an additional 210 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.